The company issues announcements regarding the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
Copenhagen, November 30, 2017 - In accordance with Section 10 of the Danish Statutory Order on Issuers’ Disclosure Obligations, Zealand Pharma issues announcements regarding the total number of shares and voting rights in the Company at the end of a calendar month during which there have been changes to its share capital.
In Company announcement No. 51 / 2017 of November 20, 2017, Zealand announced an increase in its share capital after the exercise of employee warrants. Following the announcement, the table below lists the total number of shares and voting rights in Zealand at November 30, 2017:
|
Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| November 30, 2017 | 30,751,327 | 30,751,327 | 30,751,327 |
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on Linked-in or Twitter @ZealandPharma.
